Skip to main content
European Commission logo print header

Artificial Intelligence in Colonoscopy for Cancer Prevention

Descrizione del progetto

Prevenzione del cancro: il ruolo dell’intelligenza artificiale

La colonscopia rappresenta l’approccio tradizionale per rilevare e rimuovere i polipi precancerosi. Nonostante si ritenga che l’intelligenza artificiale contribuisca al rilevamento di cellule maligne, non esiste alcuna prova diretta del suo impatto nell’ambito della prevenzione del cancro del colon-retto. L’obiettivo principale del progetto ACCEPT, finanziato dall’UE, è stabilire l’infrastruttura di ricerca che consente il confronto diretto tra la colonscopia tradizionale e quella coadiuvata dall’intelligenza artificiale. I ricercatori utilizzeranno dati reali e informazioni di follow-up provenienti dai programmi nazionali di screening del cancro del colon-retto in Europa. I risultati forniranno prove attendibili sul ruolo dell’intelligenza artificiale nell’ambito della prevenzione del cancro e contribuiranno a divulgare tale tecnologia in tutta Europa e nel resto del mondo.

Obiettivo

Removal precancerous polyps (so-called adenomas) during colonoscopy reduces colorectal cancer incidence and mortality. We have recently developed artificial intelligence (AI) systems which optimise colonoscopy quality by aiming at increasing the detection of adenomas. However, it is unknown if this benefit of AI translates into improved cancer prevention.
To establish the role of AI in colorectal cancer prevention, we here propose a three-step research portfolio targeting individuals in the national colorectal cancer screening programmes in Norway and Poland. 1) A 1-year observational study to clarify the superiority of AI in adenoma detection in the average-risk population. 2) A cost-effectiveness analysis for cancer prevention, using real-world data obtained from the part 1 study. 3) Establishment of an infrastructure for long-term (10 years) follow-up of 40,000 individuals to quantify the effect of AI on colorectal cancer incidence.
We use propensity score matching to balance the background characteristics of the two comparing arms; AI-assisted colonoscopy and standard colonoscopy. Participants are followed through national cancer registries for ten years after cancer screening.
Our project is the first of its kind and made possible by the unique collaboration of world-class environments in clinical epidemiology and medical device assessment with world-leading AI developers. The project will enable evidence-based implementation of AI technologies into nationwide cancer screening programmes in Europe and the world.
The project’s achievement will be maximised through detailed plans for training, monitoring, management, exploitation, dissemination, and communication. While adding essential competence to the host institution, this project will increase the applicant’s skill, especially in epidemiologic aspects, helping him obtain an independent academic position in translational research of AI for medicine.

Meccanismo di finanziamento

MSCA-IF-EF-ST - Standard EF

Coordinatore

UNIVERSITETET I OSLO
Contribution nette de l'UE
€ 214 158,72
Indirizzo
PROBLEMVEIEN 5-7
0313 Oslo
Norvegia

Mostra sulla mappa

Regione
Norge Oslo og Viken Oslo
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
€ 214 158,72